Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1‐Positive NSCLC or NTRK‐Positive Solid Tumors
ABSTRACT To support the benefit–risk assessment and dose justification of repotrectinib for patients with c‐ros oncogene 1 (ROS1) positive non‐small cell lung cancer (NSCLC) or neurotrophin receptor tyrosine kinase (NTRK)‐positive solid tumors, exposure–response analyses were conducted. The analysis...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2025-12-01
|
| Edice: | CPT: Pharmacometrics & Systems Pharmacology |
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/psp4.70102 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|